Kaspar Rufibach

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Venues

Pharmaceutical statistics

Trials

Biometrical journal. Biometrische Zeitschrift

F. Hoffmann-La Roche

This page only lists publications with an associated author ORCID identifier.

Affiliation History

F. Hoffmann-La Roche May 01 2012

Switzerland

Senior Principal Statistical Scientist :: Methods, Collaboration, and Outreach Group (MCO), Department of Biostatistics

Publications

Kaspar Rufibach, Jan Beyersmann, Tim Friede, Claudia Schmoor, Regina Stegherr
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and assessment of existing guidelines. Trials 25 (1) (2024)
Kaspar Rufibach, Jan Beyersmann, Tim Friede, Claudia Schmoor, Regina Stegherr
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and assessment of existing guidelines. Trials 25 (1) (2024)
Kaspar Rufibach, Lynda Grinsted, Jiang Li, Hans Jochen Weber, Cheng Zheng, Jiangxiu Zhou
Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions. Pharmaceutical statistics (2023)
Steven Sun, Hans-Jochen Weber, Emily Butler, Kaspar Rufibach, Satrajit Roychoudhury
Estimands in hematologic oncology trials. Pharmaceutical statistics 20 (4) (2021)
Juliane Manitz, Natalia Kan-Dobrosky, Hannes Buchner, Marie-Laure Casadebaig, Evgeny Degtyarev, Jyotirmoy Dey, Vincent Haddad, Fei Jie, Emily Martin, Mindy Mo, Kaspar Rufibach, Yue Shentu, Viktoriya Stalbovskaya, Rui Sammi Tang, Godwin Yung, Jiangxiu Zhou
Estimands for overall survival in clinical trials with treatment switching in oncology. Pharmaceutical statistics (2021)
Björn Bornkamp, Kaspar Rufibach, Jianchang Lin, Yi Liu, Devan V Mehrotra, Satrajit Roychoudhury, Heinz Schmidli, Yue Shentu, Marcel Wolbers
Principal stratum strategy: Potential role in drug development. Pharmaceutical statistics 20 (4) (2021)
Regina Stegherr, Jan Beyersmann, Valentine Jehl, Kaspar Rufibach, Friedhelm Leverkus, Claudia Schmoor, Tim Friede
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study. Biometrical journal. Biometrische Zeitschrift 63 (3) (2020)
Kaspar Rufibach, Dominik Heinzmann, Annabelle Monnet
Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia. Pharmaceutical statistics 19 (1) (2019)
Kaspar Rufibach
Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond. Pharmaceutical statistics 18 (2) (2018)

Kaspar Rufibach.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Kaspar Rufibach